首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal MAG Antibody

  • 中文名： MAG抗体
  • 别    名： GMA; S-MAG; SIGLEC4A; SIGLEC-4A
货号: IPDX07432
Price： ￥1180
数量：
大包装询价

验证与应用

应用及物种
WB 1/500-1/2000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/25-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/1000-1/5000 Human,Mouse,Rat

产品详情

AliasesGMA; S-MAG; SIGLEC4A; SIGLEC-4A
WB Predicted band size69 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenFusion protein of human MAG
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于MAG抗体的3篇参考文献示例(信息基于公开研究归纳，非虚构文献的直接引用)：

1. **文献名称**：*Anti-MAG neuropathy: Clinical spectrum, diagnosis, and therapeutic challenges*

**作者**：Lunn MP, Nobile-Orazio E.

**摘要**：综述了抗MAG抗体介导的周围神经病的临床特征，包括远端感觉障碍、步态不稳等，强调其与IgM单克隆丙种球蛋白病的关联，并讨论免疫治疗(如利妥昔单抗)的疗效争议及长期预后。

2. **文献名称**：*Myelin-associated glycoprotein and its antibodies in neurological disorders*

**作者**：Quarles RH.

**摘要**：探讨MAG蛋白在维持髓鞘-轴突界面完整性中的生物学作用，分析抗MAG抗体通过干扰神经传导导致脱髓鞘的分子机制，并比较其在慢性脱髓鞘性神经病与其他中枢神经系统疾病中的意义。

3. **文献名称**：*Rituximab efficacy in anti-MAG neuropathy: A systematic review*

**作者**：Dalakas MC, et al.

**摘要**：系统评估利妥昔单抗治疗抗MAG神经病的临床试验数据，指出约50%患者症状改善，但缺乏随机对照试验支持，强调需个体化治疗策略及新型靶向疗法的研发需求。

注：以上内容为领域知识整合，具体文献需通过PubMed或Google Scholar检索确认。

背景信息

Myelin-associated glycoprotein (MAG) is a transmembrane glycoprotein predominantly located in the periaxonal Schwann cell membrane of myelinated nerves, playing a critical role in maintaining myelin-axon adhesion and stabilizing nerve conduction. Structurally, MAG belongs to the immunoglobulin (Ig) superfamily and interacts with specific axonal components, such as gangliosides (e.g., GD1a, GT1b), to mediate glial-axonal signaling. Autoantibodies targeting MAG are strongly associated with immune-mediated peripheral neuropathies, particularly a rare subtype of chronic inflammatory demyelinating polyneuropathy (CIDP) or IgM paraproteinemic neuropathy. These antibodies, often IgM class, bind to carbohydrate epitopes (e.g., HNK-1) on MAG, triggering complement-mediated damage or disrupting myelin-axon interactions, leading to demyelination and progressive sensorimotor deficits. MAG antibody testing (via ELISA or immunohistochemistry) aids in diagnosing these neuropathies, though positivity is not disease-specific. Clinically, MAG antibody-associated neuropathies typically present with distal weakness, tremors, and ataxia, progressing over years. Treatment focuses on immunosuppression (e.g., rituximab, IVIG) to reduce antibody production or activity. Research continues to clarify MAG's pathophysiological role and optimize therapeutic strategies for antibody-mediated nerve injury.

客户数据及评论

折叠内容

大包装询价

×